h3 Immunocore Holdings plc Reports Q2 2024 Financial Resultsh3p Immunocore Holdings plc has reported
Intellectia.AI Updated: 1970-01-01
Immunocore Holdings plc Reports Q2 2024 Financial Results
Immunocore Holdings plc has reported its financial results for the quarter ending June 30, 2024. Below is a detailed analysis of the financial metrics and outcomes discussed in the earnings release:
Key Financial Metrics
| Metric | Q2 2024 | Q2 2023 | YoY Change (%) | Consensus Estimates | Q1 2024 | QoQ Change (%) |
|---|---|---|---|---|---|---|
| Total Revenue | $75.3M | $59.7M | +26.1% | $74.58M | $70.4M | +6.97% |
| Earnings Per Share (EPS) | -$0.23 | -$0.43 | +46.5% | -$0.48 | -$0.37 | +37.84% |
Immunocore Holdings plc has exhibited strong year-over-year growth in total revenue of 26.1%, surpassing the consensus estimate slightly. The company has also shown significant improvement in EPS, reducing its loss from $-0.43 to $-0.23. Quarter-over-quarter, the company has shown consistent improvement, with a 6.97% uptick in revenue and a significant 37.84% improvement in EPS.
Segment Performance
| Segment | Q2 2024 Revenue | Q2 2023 Revenue | Previous Guidance (%) |
|---|---|---|---|
| United States | $55.6M | $39.2M | 30% |
| Europe | $15.4M | $14.3M | 12% |
| International | $4.3M | $2.0M | 115% |
The U.S. segment displayed significant growth, while Europe exhibited modest gains. Meanwhile, the International segment has shown an outstanding 115% increase, aligning with Immunocore Holdings plc’s guidance and ongoing global expansion efforts.
Comments from Officers
Unfortunately, the report did not include specific comments from company officers.
Dividend and Share Repurchase Program
There was no mention of any announced dividends or share repurchase programs in the earnings release.
Forward Guidance
The earnings release did not provide specific forward guidance.
Stock Price Movement
| Metric | Post-Event |
|---|---|
| Stock Price Change (%) | -3.07% |
The company's stock price experienced a decrease of 3.07% following the earnings release.
In summary, Immunocore Holdings plc delivered robust year-over-year and quarter-over-quarter growth, surpassing revenue estimates and improving EPS. However, the market reacted unfavorably, resulting in a slight decline in the stock price.
No changes were necessary. The report is well-organized and contains useful information for investors.